Design of <i>N</i>‑Benzoxaborole Benzofuran GSK8175Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor by Pek Y. Chong (1833568)

“…We previously described the discovery of GSK5852 (<b>1</b>), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an <i>N</i>-benzyl boronic acid was essential for potent antiviral activity. …”

Free energy landscape (FEL) analysis for the SP domain of native PC and its mutant structures over 200 ns MD simulation times. by Mahvash Farajzadeh-Dehkordi (17468232)

FoxO3a-dependent mechanism of miR-150-5p in regulating pyroptosis in ox-LDL-stimulated RAW264.7 macrophages. (A-E) FoxO3a and ARC expression analyzed by (A-C) RT-qPCR and (D-E) Wes... by Ping-yu Cai (12389929)

Subjects:

Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant by Ittipat Meewan (7455041)

“…However, in the same assay, the potency of the approved drug, simeprevir, decreased 5.7-fold for the mutant enzyme relative to the wild type. …”

MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

Decreased echinocandin susceptibility in <i>Candida parapsilosis</i> causing candidemia and emergence of a pan-echinocandin resistant case in China by Yating Ning (11264310)

Apoptosis inhibitor prevented the decrease of IIL ESP-induced TJs expression and alleviated barrier disruption of Caco-2 monolayer. by Qi Qi Lu (17721401)

Brain and liver GCase activity are significantly decreased in heterozygous <i>GBA1</i> D409V KI mice, with varying differences in glucosphingolipid lipids in brain and liver. by Nicole K. Polinski (10947787)

“…(A-B) GCase levels as assessed by the CBE/4-MU method are significantly decreased in the het <i>GBA1</i> D409V KI mice at 5 months of age in both brain (A) and liver (B). …”

DDX5 and DDX17 decrease viral gene expression during KSHV lytic reactivation in BCBL1 cells and do not affect KSHV entry in HUVEC. by Praneet Kaur Sandhu (21156149)

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Cry variables. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Competition localization increases with growth rate or the distances between colonies, and decreases with the resource diffusion constant. by Jeremy M. Chacón (8259792)

VMH Menin knockdown induced decreased hippocampal D-serine levels and impaired synaptic functions. by Lige Leng (14803241)

Metformin/rifampicin combination decreases <i>S</i>. <i>aureus</i> load and persisters in Mice. by Xiao-Qi Lin (9548375)

CR increases ROS and decreases the mtDNA copy number in MLH1 deficient cells. by Berna Somuncu (12770334)

Inhibition of <i>miR-750</i> led to decreased egg production in female schistosomes. by Pengfei Du (513926)

“…<p>A) RT-qPCR analysis of <i>miR-750</i> expression in female and male schistosomes. ns means no statistically significant difference. …”

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

Depletion or deletion of <i>USP22</i> in MCF10A cells that stably overexpress ERBB2 did not affect the levels of ERBB2. by Xianghong Kuang (17811238)

The decreased inflammation in the liver of the CD45.2⁺ recipient mice that were adoptively transferred with InCsEVs-BMDMs. by Beibei Zhang (509356)